Can you believe it's already the last day of #HCAATPASummit? Randy Iskowitz and Jeff Wunderlich have enjoyed the sessions and the conversations they have had over the last two days and are looking forward to making the most of today. There is still time to 𝒔𝒄𝒉𝒆𝒅𝒖𝒍𝒆 𝒂 15-𝒎𝒊𝒏𝒖𝒕𝒆 𝒎𝒆𝒆𝒕𝒊𝒏𝒈 𝒘𝒊𝒕𝒉 𝒕𝒉𝒆𝒎 𝒃𝒚 𝒄𝒍𝒊𝒄𝒌𝒊𝒏𝒈 𝒕𝒉𝒆 𝒍𝒊𝒏𝒌 𝒃𝒆𝒍𝒐𝒘. Learn more about how Medical Review Institute of America, LLC (𝐌𝐑𝐈𝐨𝐀) can help with your 𝘴𝘱𝘦𝘤𝘪𝘢𝘭𝘵𝘺 𝘮𝘢𝘵𝘤𝘩𝘦𝘥 𝘢𝘯𝘥 𝘱𝘦𝘦𝘳-𝘵𝘰-𝘱𝘦𝘦𝘳 𝘳𝘦𝘷𝘪𝘦𝘸 𝘯𝘦𝘦𝘥𝘴, especially when it comes to the challenge of 𝒈𝒆𝒏𝒆 𝒂𝒏𝒅 𝒄𝒆𝒍𝒍 𝒕𝒉𝒆𝒓𝒂𝒑𝒚 𝒓𝒆𝒗𝒊𝒆𝒘𝒔 𝒂𝒏𝒅 𝑮𝑳𝑷-1 𝒓𝒆𝒗𝒊𝒆𝒘𝒔. https://lnkd.in/gEj__TPH #hcaa #HCAATPASummit #healthcare #healthplans #TPAs #teammrioa
Medical Review Institute of America, LLC’s Post
More Relevant Posts
-
"It's great to see a willingness to learn and a willingness to take some risk. We should take advantage of this partnership because we're all learning together and delivering value to patients." - Miguel Forte, Kiji Therapeutics The clinical development roadmap for cell and gene therapy is ever-changing. How can we prepare for a more integrated approach to clinical trial design and execution? Brought to you by Precision For Medicine and hosted by Endpoints News. WATCH NOW: https://hubs.ly/Q02xXtRJ0 #CGTx #CGTxDay2024 #CellTherapy #GeneTherapy #transformativemedicine
To view or add a comment, sign in
-
"It's great to see a willingness to learn and a willingness to take some risk. We should take advantage of this partnership because we're all learning together and delivering value to patients." - Miguel Forte, Kiji Therapeutics The clinical development roadmap for cell and gene therapy is ever-changing. How can we prepare for a more integrated approach to clinical trial design and execution? Brought to you by Precision For Medicine and hosted by Endpoints News. WATCH NOW: https://hubs.ly/Q02xXpMD0 #CGTx #CGTxDay2024 #CellTherapy #GeneTherapy #transformativemedicine
To view or add a comment, sign in
-
"It's great to see a willingness to learn and a willingness to take some risk. We should take advantage of this partnership because we're all learning together and delivering value to patients." - Miguel Forte, Kiji Therapeutics The clinical development roadmap for cell and gene therapy is ever-changing. How can we prepare for a more integrated approach to clinical trial design and execution? Brought to you by Precision For Medicine and hosted by Endpoints News. WATCH NOW: https://hubs.ly/Q02ybr8t0 #CGTx #CGTxDay2024 #CellTherapy #GeneTherapy #transformativemedicine
To view or add a comment, sign in
-
Vice President - Program Lead I Organisational transformation I Digital transformation I Partnership evolution I Strategy development and implementation I Digital hub builder
#Gene and #cell-based therapies have the potential to provide targeted and personalized treatments, according to Charité - Universitätsmedizin Berlin and Bayer. They are a beacon of hope for people for whom conventional therapies have failed or for whom there is no treatment so far. With Charité and Bayer, two partners for major medical progress are coming together who will establish a new center for gene and cell therapy in #Berlin, which is to be established in 2025. More information in first comment #healthforall #teambayer
To view or add a comment, sign in
-
#ASGCTPatientEducation provides the public with expert insights on timely topics in gene and cell therapy. In this quarter's Community Quick Takes conversation, #CGT experts discuss Access to Approved CGTs, from therapy development and eligibility to coverage, referral, and treatment logistics. 🔍 Get rapid insights from experts: David Segal, PhD Rachel Salzman, DVM Rayne Rouce, MD Andrew Campbell, MD 🌐 Watch the full video and learn more here: https://lnkd.in/gUv4yRcn As the CGT field expands, so will the need for individuals to keep current on accurate, timely scientific findings. If you want to learn more about CGT and further connect with those working to change the way individuals view treatments for rare diseases, consider becoming an ASGCT member and subscribing to The Advocate! Details below!
To view or add a comment, sign in
-
This is a really important discussion hosted by the American Society of Gene & Cell Therapy. In order to improve patient access to transformative #CGT medicines, we need to consider the downstream effects of how trial designs inform drug labels, which are later referenced by payers making reimbursement determinations that may ultimately exclude some patients. We need thoughtful drug development and evidence generation strategies in both the pre- and post-approval settings as a means of effectively expanding access. #ASGCTPatientEducation
#ASGCTPatientEducation provides the public with expert insights on timely topics in gene and cell therapy. In this quarter's Community Quick Takes conversation, #CGT experts discuss Access to Approved CGTs, from therapy development and eligibility to coverage, referral, and treatment logistics. 🔍 Get rapid insights from experts: David Segal, PhD Rachel Salzman, DVM Rayne Rouce, MD Andrew Campbell, MD 🌐 Watch the full video and learn more here: https://lnkd.in/gUv4yRcn As the CGT field expands, so will the need for individuals to keep current on accurate, timely scientific findings. If you want to learn more about CGT and further connect with those working to change the way individuals view treatments for rare diseases, consider becoming an ASGCT member and subscribing to The Advocate! Details below!
To view or add a comment, sign in
-
🎙️🎧 From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II) In this episode, Fierce Pharma's Fraiser Kansteiner sits down with Delara Motlagh, head of cell therapy at Catalent Pharma Solutions; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. Together, they discuss cell collection, the critical first step in advanced therapy manufacturing, and the importance of locking in process decisions early and how to effectively scale projects from the lab to the clinic and eventually to the market. Listen below ⬇️🎧 #CellGeneTherapy #CGT #CellandGeneTherapies
To view or add a comment, sign in
-
🎙️🎧 From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II) In this episode, Fierce Pharma's Fraiser Kansteiner sits down with Delara Motlagh, head of cell therapy at Catalent Pharma Solutions; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. Together, they discuss cell collection, the critical first step in advanced therapy manufacturing, and the importance of locking in process decisions early and how to effectively scale projects from the lab to the clinic and eventually to the market. Listen below ⬇️🎧 #CellGeneTherapy #CGT #CellandGeneTherapies
From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II)
To view or add a comment, sign in
-
Tune-in to our presentation this week at #ASGCT2024 where we highlight how we used AI to engineer an allele selective antisense oligonucleotide investigational therapy and an investigator-initiated clinical trial received approval to treat a pediatric patient with an ultra-rare disease within a year. Creyon has built the first and only platform capable of engineering for safety first, translating new target discoveries to OBMs with optimal pharmacological properties. Coupled with our aptamer-based delivery technologies, Creyon Bio is unlocking the full potential of OBMs for common and rare diseases alike. https://lnkd.in/dezfE_V9 American Society of Gene & Cell Therapy, Nicole Coufal, TNPO2 Foundation
To view or add a comment, sign in
-
🎙️🎧 From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II) In this episode, Fierce Pharma's Fraiser Kansteiner sits down with Delara Motlagh, head of cell therapy at Catalent Pharma Solutions; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. Together, they discuss cell collection, the critical first step in advanced therapy manufacturing, and the importance of locking in process decisions early and how to effectively scale projects from the lab to the clinic and eventually to the market. Listen below ⬇️🎧 #CellGeneTherapy #CGT #CellandGeneTherapies
From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II)
To view or add a comment, sign in
3,379 followers
Medical Review Institute of America
1moGreat Event!